Ensysce Biosciences, Inc. Common Stock
$0.45
$0.00 (+1.05%)
$0.44Day Range$0.47
Key Statistics
Market Cap
$8.71M
Shares Outstanding
19.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jul 1, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$0.45
Day High
$0.47
Day Low
$0.44
Volume
391.1K
VWAP
$0.45
Prev Close
$0.45
Transactions
--
Acc. Volume
--
About Ensysce Biosciences, Inc. Common Stock
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
PHARMACEUTICAL PREPARATIONSSIC 283410 employees7946 IVANHOE AVENUE, LA JOLLA, CA, 92037(858) 263-4196IPO Jul 1, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001716947
- Composite FIGI
- BBG00JFF4174
- Share Class FIGI
- BBG00JFF4183
- Ticker Root
- ENSC
- SIC Code
- 2834
About Ensysce Biosciences, Inc. Common Stock (ENSC) Stock
Ensysce Biosciences, Inc. Common Stock (ENSC) closed the 2026-09-17 session at $0.45, up 1.05% versus the previous close (+0.00). The stock opened at $0.45 and traded between $0.44 and $0.47 during that session. Session trading volume was 391K shares. The volume-weighted average price (VWAP) is $0.45.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Ensysce Biosciences, Inc. Common Stock has a market capitalization of $8.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ENSC is listed on the XNAS exchange. The company employs approximately 10 people. Ensysce Biosciences, Inc. Common Stock is headquartered in LA JOLLA, CA. The recorded listing date is 2021-07-01.
On this page you can find market ENSC stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.